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Pataia V, McIlvride S, Papacleovoulou G, Ovadia C, McDonald
JAK, Wahlström A, Jansen E, Adorini L, Shapiro D, Marchesi
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bile acid profile in a mouse model of gestational hypercholanemia. Am
J Physiol Gastrointest Liver Physiol 319: G197–G211, 2020. First
published June 29, 2020; doi:10.1152/ajpgi.00126.2020.—Intrahe-
patic cholestasis of pregnancy (ICP) is characterized by elevated
maternal circulating bile acid levels and associated dyslipidemia. ICP
leads to accumulation of bile acids in the fetal compartment, and the
elevated bile acid concentrations are associated with an increased risk
of adverse fetal outcomes. The farnesoid X receptor agonist obetich-
olic acid (OCA) is efficient in the treatment of cholestatic conditions
such as primary biliary cholangitis. We hypothesized that OCA
administration during hypercholanemic pregnancy will improve ma-
ternal and fetal bile acid and lipid profiles. Female C57BL/6J mice
were fed either a normal chow diet, a 0.5% cholic acid (CA)-
supplemented diet, a 0.03% OCA-supplemented diet, or a 0.5% CA
0.03% OCA-supplemented diet for 1 wk before mating and through-
out pregnancy until euthanization on day 18. The effects of CA and
OCA feeding on maternal and fetal morphometry, bile acid and lipid
levels, and cecal microbiota were investigated. OCA administration
during gestation did not alter the maternal or fetal body weight or
organ morphometry. OCA treatment during hypercholanemic preg-
nancy reduced bile acid levels in the fetal compartment. However,
fetal dyslipidemia was not reversed, and OCA did not impact maternal
bile acid levels or dyslipidemia. In conclusion, OCA administration
during gestation had no apparent detrimental impact on maternal or
fetal morphometry and improved fetal hypercholanemia. Because
high serum bile acid concentrations in ICP are associated with
increased rates of adverse fetal outcomes, further investigations into
the potential use of OCA during cholestatic gestation are warranted.
NEW & NOTEWORTHY We used a mouse model of gestational
hypercholanemia to investigate the use of obeticholic acid (OCA), a
potent FXR agonist, as a treatment for the hypercholanemia of
intrahepatic cholestasis of pregnancy (ICP). The results demonstrate
that OCA can improve the fetal bile acid profile. This is relevant not
only to women with ICP but also for women who become pregnant
while receiving OCA treatment for other conditions such as primary
biliary cholangitis and nonalcoholic steatohepatitis.
bile acids; FXR; intrahepatic cholestasis of pregnancy
INTRODUCTION
Intrahepatic cholestasis of pregnancy (ICP) is a cholestatic
condition that affects 0.4–2.2% of pregnancies in North Amer-
ica and Western Europe but is more common in Chile and
Bolivia, where it can affect 1.5–4% of pregnancies (11, 13,
44). ICP typically presents from 30 wk of gestation, and the
main symptom is persistent generalized itch. Diagnosis is made
in women with an elevation of serum bile acids. ICP is associated
with maternal dyslipidemia (12, 27) and increased risk of gesta-
tional diabetes mellitus (26, 27, 49). The most common treatment
for ICP is ursodeoxycholic acid (UDCA) administration, but not
all patients respond (8, 9, 18), and a recent trial revealed no benefit
for adverse perinatal outcomes (8).
The adverse fetal outcomes that occur in ICP include pre-
term birth, fetal hypoxia, meconium-stained amniotic fluid,
stillbirth, and prolonged admission to the neonatal unit (19).
Maternal bile acid levels have been reported to be positively
correlated to fetal bile acid levels, and incremental rises in
maternal serum bile acids 40 mol/L are associated with
higher risk of adverse fetal outcomes (7, 9, 21). The fetal lipid
profile has also been shown to be affected by maternal choles-
tasis, with increased cholesterol accumulation in the fetal liver
and placenta in a mouse model of gestational cholestasis and in
the umbilical cord of neonates exposed to maternal ICP (41).
It has previously been described that during normal preg-
nancy the activity of farnesoid X receptor (FXR), the master
nuclear receptor regulating bile acid homeostasis, is decreased,
allowing for a maternal procholestatic profile even during
normal gestation (31, 33, 39). However, it is thought that in
ICP the combination of genetic susceptibility, elevated repro-
ductive hormones, and environmental factors may lead to an
exacerbation of the procholestatic profile found in pregnancy
and result in a pathological rise of bile acid levels (17).
In recent years, synthetic FXR agonists have been devel-
oped. In particular, the semisynthetic bile acid obeticholic acid
(OCA) has more than 100 times higher affinity for FXR than its
most potent natural ligand, chenodeoxycholic acid (CDCA),Correspondence: C. Williamson (catherine.williamson@kcl.ac.uk).
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and has been shown to promote bile acid efflux and reduce bile
acid synthesis (51). Clinical trials of OCA have shown prom-
ising results for the treatment of primary biliary cholangitis
(PBC) and nonalcoholic steatohepatitis (NASH) (2).
In this study, we used a previously established model of
0.5% cholic acid (CA) feeding in pregnancy to mimic the
hypercholanemia of ICP (32, 41). Because of the key role of
FXR in bile acid synthesis, transport, and excretion, as well as
regulation of lipid metabolism, we hypothesized that activation
of FXR by OCA could improve maternal and fetal hyper-
cholanemia and dyslipidemia.
MATERIALS AND METHODS
Animal experiments. Six- to eight-week-old C57BL/6J mice were
purchased from Envigo and allowed to acclimatize for 1 wk before
any experimental procedures were carried out. All mice were kept on
a 12:12-h light-dark cycle with access to food and water ad libitum.
All procedures were approved by the Animal Welfare and Ethical
Review Body at King’s College London and carried out according to
the UK Animals (Scientific Procedures) Act 1986. All diets were
supplied by Special Diet Services.
We have previously shown that cholic acid (CA) feeding can
induce maternal hypercholanemia in mice (32, 41). Female mice were
assigned to either standard maintenance or breeding diet (CRM),
referred to as normal chow diet (NC), a 0.5% CA-supplemented CRM
diet, a 0.03% obeticholic acid (OCA; Intercept Pharmaceuticals)-
supplemented CRM diet, or a 0.5% CA  0.03% OCA (CA 
OCA)-supplemented CRM diet 1 wk before mating and maintained on
their assigned diet for the duration of the experimental procedures.
The dose of OCA was selected based on previously published liter-
ature (4) and was equivalent to 42 mg·kg1·day1. Females were
mated to control males and checked daily for the presence of a
copulatory plug. The day of identification of the copulatory plug was
considered day 1 of pregnancy (D1). Body weight of pregnant females
was measured on days 7 (D7), 14 (D14), and 18 (D18) of pregnancy.
On D18, females were fasted for 4 h and euthanized by CO2 inhala-
tion. Maternal and fetal sera were collected, and pup number per litter
was assessed. Maternal liver, subcutaneous white adipose tissue
(sWAT), gonadal white adipose tissue (gWAT), brown adipose tissue
(BAT), and fetal and placental weight were measured. Maternal liver,
terminal ileum, fetal liver, and placenta were collected and snap-
frozen. Nonpregnant control female mice were maintained on the
same diets as pregnant females for an equivalent length of time and
were assessed for the same parameters.
Gene expression studies. Total RNA was extracted from frozen
tissue samples using the RNeasy Mini kit (Qiagen) according to the
manufacturer’s guidance. After RNA extraction, 1 g of total RNA
was reverse transcribed using SuperScript II Reverse Transcriptase
(Invitrogen). RNaseOUT Recombinant Ribonuclease Inhibitor (Invit-
rogen) was used as an RNase inhibition step. Assessment of the
expression of target genes of interest was assessed using quantitative
RT-PCR with a ViiA 7 Real Time PCR System (Thermo Fisher
Scientific) by adding cDNA in duplicate to a 384-well plate, followed
by a reaction mix of 1 SYBR Green Jumpstart Readymix (Sigma-
Aldrich) and 1 M of forward/reverse primers. The housekeeping
gene cyclophilin b was used as an internal reference for quantification
of relative gene expression. Primer sequences of genes of interest are
provided in Supplemental Table S1 (Supplemental Material for this
article can be found online at https://doi.org/10.6084/m9.figshare.
12497714).
Serum and tissue lipid quantification. Serum and tissue lipid
content were extracted and measured as previously described (38). In
brief, frozen tissues of interest were homogenized in Hanks’ Balanced
Salt Solution using a TissueLyser II (Qiagen) system. Samples were
then centrifuged at 12,000 rpm for 15 min at 4°C (Rotina 420R
Benchtop Centrifuge, Hettich, Germany). The supernatant was dis-
carded. The pellet was resuspended in 500 L of lysis buffer con-
taining 0.125 M potassium phosphate, 1 mM EDTA, and 0.1% Triton
X-100 at pH 7.4. Samples were sonicated at 4°C for 8 min in a
Bioruptor Plus (4 cycles of sonication for 30 s, followed by 4 cycles
of resting for 30 s). Samples were subsequently centrifuged at 10,000
rpm for 15 min at 4°C. Total cholesterol, LDL cholesterol, HDL
cholesterol, triglycerides (TGs), free fatty acids (FFAs), and total
protein were measured in plasma and tissue extracts with an Unicel
DxC 800 autoanalyzer (Beckman-Coulter) using dedicated kits, with
the exception of FFAs which were measured using a kit from Wako
Diagnostics (Germany). The measurements in the tissue extracts were
normalized with the protein content of each individual tissue sample.
Serum and cecal bile acid quantification. Measurements of serum
and cecal bile acids were performed on an ultraperformance liquid
chromatography Alliance 2695 system coupled to a Xevo TQ mass
spectrometer using a SunFire C18 column, as previously described (1,
45). Analytes were detected using selected ion monitoring and quan-
tified against deuterium-labeled internal standards. Quantification was
achieved by comparison of peak height of molecular anions or
negative daughter to the peak height of the deuterated internal stan-
dards.
16S rRNA gene sequencing analysis. Cecal samples were homog-
enized, and DNA was extracted using the QIAamp Fast DNA Stool
Mini Kit (Qiagen) according to the manufacturers’ protocol. Sample
libraries were prepared as previously described (28) using the V1-V2
primers (35). An Illumina MiSeq platform was used to perform the
sequencing with the MiSeq Reagent Kit version 3 and paired-end
300-bp chemistry (Illumina, Inc.). Mothur software (version 1.35.1;
www.mothur.org) was used for data analysis, following the MiSeq
SOP Pipeline (47). The Silva bacterial database (www.arb-silva.de/)
was used for sequence alignments, and sequences were classified
according to the RDP database reference sequence files using the
Wang method (16). The UniFrac weighted distance matrix created by
Mothur was used to produce nonmetric multidimensional scaling
(NMDS) plots and PERMANOVA (permutational multivariate anal-
ysis of variance) P values, and analysis was carried out using the
Vegan library (6) within the R statistical software (www.r-projec-
t.org). Bacterial relative abundance was expressed as extended error
bar plots using the Statistical Analysis of Metagenomic Profiles
software package and analyzed by White’s nonparametric t test with
Benjamini-Hochberg False Discovery Rate (FDR). The -diversity
(Shannon diversity index, H=) was calculated using Mothur, and
Tukey’s Honestly Significant Difference test was performed using
IBM SPSS Statistics Software version 23. P and q values of 0.05 were
considered to be significant.
Statistical analysis. All values are shown as means	 SE. Statisti-
cal analysis was performed using GraphPad Prism 7 software. One-
way ANOVA followed by a Newman-Keuls post hoc test was used,
with a significance cutoff of P  0.05. Statistical analysis of 16S
rRNA gene sequencing data is detailed in the relevant section above.
RESULTS
OCA administration during pregnancy does not negatively
impact maternal or fetal morphometry. We first aimed to estab-
lish the effect of hypercholanemia and OCA supplementation
during pregnancy on body weight and organ morphometry.
During pregnancy, no body weight differences were seen
between groups, except on D7 when CA and CA  OCA-fed
females were significantly lighter than OCA-fed females
(Fig. 1A). Although no body weight differences were registered
on D18 gestation, pregnant females fed a CA diet had in-
creased liver weight and decreased gWAT weight regardless of
OCA cofeeding (Fig. 1B). A trend for decreased sWAT weight
was also seen in pregnant CA and CA  OCA groups (Fig.
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1B). OCA supplementation alone did not affect body weight or
organ morphometry (Fig. 1B).
Despite the changes in maternal liver and gWAT mor-
phometry in the CA and CA  OCA-fed groups, no changes
in pup number, pup weight, or placental weight were reg-
istered (Fig. 1C).
Outside of pregnancy, both CA and CA  OCA nonpreg-
nant females were lighter than NC- and OCA-supplemented
Fig. 1. Effects of hypercholanemia and obeticholic acid (OCA) treatment during pregnancy on body and organ morphometry. A: body weight of pregnant females
on days 1 (D1), 7 (D7), 14 (D14), and 18 (D18). #P 0.05 for cholic acid (CA) vs. OCA; *P 0.05 for CA OCA vs. OCA groups. B: weight of liver, gonadal
white adipose tissue (gWAT), subcutaneous white adipose tissue (sWAT), and brown adipose tissue (BAT) of pregnant females on D18. C: pup number, pup
weight, and placenta weight of D18 fetuses. *P  0.05 in comparisons vs. normal chow diet (NC) and OCA groups. Data are presented as means 	 SE; n 

6–9 mice.
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females on D18 (Supplemental Fig. S1A). This weight differ-
ence likely reflected a decrease in gWAT, sWAT, and BAT
depot weight despite an increase in liver weight (Supplemental
Fig. S1B).
These results demonstrate that OCA administration either
alone or to hypercholanemic pregnant females did not nega-
tively impact maternal or fetal body or organ morphometry.
OCA administration during hypercholanemic pregnancy re-
duces fetal hypercholanemia. We next investigated whether
OCA administration ameliorated the maternal and fetal bile
acid profiles during hypercholanemic gestation. In pregnant
females, CA feeding led to a significant increase in total serum
bile acid levels, CA, deoxycholic acid (DCA), taurocholic acid
(TCA), and taurodeoxycholic acid (TDCA) compared with NC
controls, confirming that CA-feeding induces maternal hyper-
cholanemia, as has previously been described (32, 41). CA 
OCA cosupplementation did not ameliorate total serum bile
acid levels, although total unconjugated bile acids were signif-
icantly reduced compared with CA alone due to changes in CA
(P  0.05) and DCA (P  0.05) (Fig. 2A).
In nonpregnant females, total bile acids and DCA, TCA,
and TDCA levels were significantly elevated by CA feeding
and were not reduced by CA  OCA cofeeding (Supple-
mental Fig. S2).
In the fetal compartment, maternal hypercholanemia led to a
significant rise in fetal serum total bile acids (Fig. 2B). How-
ever, total serum bile acid levels were 29.9% lower in fetuses
from mothers fed a CAOCA diet compared with CA alone,
although still higher than NC controls (Fig. 2B). This was due
to decreased concentrations of DCA, TCA, TDCA, and, in
particular, CA (Fig. 2B). Maternal OCA feeding alone did not
change fetal bile acid concentrations, although the presence of
OCA and T-OCA in the fetal circulation suggests that OCA is
able to cross the placenta (Fig. 2B).
Overall, OCA administration to hypercholanemic females
did not significantly ameliorate maternal hypercholanemia but
improved the fetal bile acid profile.
OCA administration alone reduces cecal bile acid levels.
Cecal bile acid concentrations were also measured. As ex-
pected in the cecum, bile acids were largely unconjugated
Fig. 2. Effects of hypercholanemia and obeticholic acid (OCA) treatment during pregnancy on serum bile acid (BA) profile. A: serum total BAs, unconjugated
BA, and taurine-conjugated BA levels in day 18 (D18) pregnant females; n 
 6 mice /group. B: serum total BA, unconjugated BA, and taurine-conjugated BA
levels in D18 fetuses; n 
 4–6 mice /group. *P  0.05 in comparisons vs. normal chow diet (NC) and OCA groups; ‡P  0.05 in comparisons vs. all groups;
$P  0.05 in comparisons vs. OCA; †P  0.05 in comparisons vs. NC and CA groups. Data are presented as means 	 SE.
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(Fig. 3). Total cecal bile acid levels were significantly in-
creased in mice fed CA  OCA compared with CA alone;
however, this was largely due to enrichment with OCA and
also with DCA that increased in the CA-fed group (Fig. 3, A
and B). Muricholic acids levels were markedly reduced in both
CA and CA  OCA groups (Fig. 3, B and C). OCA adminis-
tration alone significantly reduced total cecal bile acid levels
compared with all other groups, which was due to an overall
reduction in bile acids (Fig. 3A). Interestingly, as seen in the
serum, T-OCA levels were significantly lower in CA  OCA
cofed mice compared with females supplemented with OCA
only, whereas OCA levels were increased (Fig. 3, B and C).
Bile acid supplementation impacts the cecal microbiome’s
microbiota composition. Conversion of primary to secondary
bile acids, as well as bile acid deconjugation, is performed by
intestinal bacteria. Because changes in bile-metabolizing bac-
teria will affect the host bile acid pool, the cecal bacterial
community was investigated by 16S rRNA gene sequencing.
Nonmetric multidimensional scaling (NMDS) analysis of
weights UniFrac distances, which shows how the microbial
communities vary between the groups, demonstrates signifi-
cant differences between all the dietary groups in pregnant
mice (Fig. 4A and Supplemental Table S2). OCA supplemen-
tation alone was the least different from NC, with CA and then
CA  OCA being more dissimilar. Differences in the relative
proportion of phyla were observed between pregnant groups
(Fig. 4B); specifically, both CA feeding and CA  OCA
cofeeding significantly increased the relative abundance of
Proteobacteria in the cecum of pregnant mice compared with
NC groups (Fig. 4C). OCA feeding alone did not significantly
impact Proteobacteria, but the relative abundance of Bacte-
roidetes was significantly decreased in pregnant females (Fig.
4C). Significant changes were also observed at genus level,
with an increase in the relative proportion of Bilophila and
Bacteroides in CA  OCA-fed mice compared with all other
groups (Fig. 4D). This was reinforced by correlation analysis
between microbiota and bile acid concentrations in the cecum,
which showed that Proteobacteria and Bacteroidetes posi-
tively correlated with OCA and negatively with T-OCA con-
centrations (Supplemental Fig. S3A). Alpha diversity (Shan-
non diversity index) plots showed that CA supplementation
alone or cofed with OCA resulted in decreased bacterial diversity
(Supplemental Fig. S3B). Pregnancy caused a significant increase
in an unclassified class of Bacteroidetes in NC controls (Supple-
mental Fig. S3C). In nonpregnant mice, NMDS analysis and alpha
diversity plots were similar to pregnant mice (Supplemental Fig.
S4, A and B). However, changes between the dietary groups
differed at phylum level; in particular, significant differences were
observed in Bacteroidetes, Firmicutes, and Proteobacteria (Sup-
plementary Fig. S4C).
OCA administration represses maternal hepatic Cyp7a1
expression via intestinal FXR. To further assess the effects of
hypercholanemia and OCA administration on bile acid homeo-
stasis during pregnancy, the expression of key genes for bile
acid homeostasis in the liver and terminal ileum was investi-
gated.
The hepatic FXR target Shp was significantly upregulated in
pregnant females fed a CA or a CA  OCA diet, and this
change was concomitant with the repression of hepatic Cyp7a1
(Fig. 5A). Both CA and CA  OCA diet increased the hepatic
expression of the bile acid transporters Bsep, Mrp3, and Mrp4
in pregnant females (Fig. 5A). Whereas OCA supplementation
alone did not induce significant hepatic Shp upregulation,
Cyp7a1 expression was significantly decreased in D18 preg-
nant females (Fig. 5A). In parallel, intestinal Shp expression
was upregulated in OCA-fed females, and intestinal Fgf15
expression was significantly increased by maternal CA, OCA,
and CA  OCA supplementation (Fig. 5B).
In nonpregnant females, relative mRNA expression fol-
lowed a very similar pattern to pregnant mice (Supplemental
Fig. S5, A and B). Of note is that lower hepatic gene expres-
sion of several FXR targets was observed in pregnant mice
compared with nonpregnant mice, regardless of diet (Table 1).
Expression of FXR targets in the terminal ileum was similarly
affected by pregnancy. In pregnant CA-fed females, Shp and
Fgf15 expression were lower than outside pregnancy (Table 2).
Shp expression levels were also lower in CA  OCA-fed
pregnant females compared with nonpregnant (Table 2).
Fig. 3. Effects of hypercholanemia and obeticholic acid (OCA) treatment during pregnancy on cecal bile acid profile. Bile acid (BA) levels in cecum of day 18
(D18) pregnant females. A: total cecal BAs. B: unconjugated BAs. C: taurine-conjugated bile acids. Data are presented as means 	 SE; n 
 6–9 mice. ‡P 
0.05 in comparisons vs. all groups; *P  0.05 in comparisons vs. normal chow diet (NC) and OCA groups.
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Overall, we conclude that despite decreased expression of
FXR target genes during pregnancy, activation of intestinal
rather than hepatic FXR can mediate OCA-induced suppres-
sion of hepatic Cyp7a1 expression.
Maternal OCA administration represses fetal hepatic Cyp7a1
expression. Given the decrease in fetal serum bile acid concen-
trations in maternal CA OCA feeding groups, the expression
of key bile acid homeostasis genes in the fetal liver and
placenta were assessed. Maternal CA feeding alone or co-
supplemented with OCA induced an upregulation of Shp ex-
pression and a concomitant reduction in Cyp7a1 and Ntcp in
the fetal liver (Fig. 6A). Of note is that whereas maternal OCA
diet alone did not have an impact on fetal hepatic Shp expres-
sion, a significant downregulation of hepatic Cyp7a1 expres-
sion was observed, albeit to a lesser extent than in groups with
maternal CA supplementation (Fig. 6A). Maternal bile acid
feeding did not have an impact on hepatic fetal Mrp3, Mrp4, or
Oatp1b2 expression (Fig. 6A).
As the placenta plays a crucial role in bile acid transport
between maternal and fetal circulations, we further sought to
determine whether maternal OCA administration had an im-
pact on placental bile acid transporter gene expression. Inter-
estingly, all maternal bile acid feeding groups showed a sig-
nificant upregulation of Abcg2 expression in the placenta (Fig.
6B). Moreover, maternal CAOCA feeding increased placen-
tal Mrp2 expression when compared against all other feeding
groups, and Oatp1b2 expression was increased compared with
NC and CA groups (Fig. 6B). Overall, we conclude that OCA
Fig. 4. Changes in cecal microbiota in pregnant mice measured by 16S rRNA gene sequencing. A: nonmetric multidimensional scaling (NMDS) plot showing
differences in bacterial community structure based on the weighted UniFrac distance metric. For P values, see Supplemental Table S2. B: changes in relative
proportion of reads at phylum level. C and D: significant changes in the average relative proportion of sequences assigned to each taxa for each dietary group
at phylum (C) and genus level (D). Data presented as extended error bar plots showing P value, effect size, and confidence interval for each taxa. Analyzed by
Kruskal-Wallis H test with Benjamini-Hochberg false discovery rate; n 
 6 mice/group. CA, cholic acid; NC, normal chow diet; OCA, obeticholic acid.
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modulates the expression of Cyp7a1 in the fetal liver and bile
acid transporters in the placenta.
OCA administration during hypercholanemic pregnancy
does not reverse maternal dyslipidemia. Cholestasis is com-
monly accompanied by dyslipidemia. Hence, we next studied
the effect of OCA administration during hypercholanemic
pregnancy on maternal and fetal serum and hepatic lipid levels.
No changes in total serum cholesterol levels were seen in
pregnant CA or CA  OCA-supplemented groups (Fig. 7A).
However, females exposed to a CA or CA  OCA diet had
Fig. 5. Expression of key bile acid homeo-
stasis genes in pregnant females. A: mRNA
expression of genes regulating bile acid syn-
thesis and transport in the liver. B: mRNA
expression of genes regulating bile acid syn-
thesis and transport in the terminal ileum.
Data are presented as means	 SE; n
 4–6
mice. *P  0.05 in comparisons vs. normal
chow diet (NC) and obeticholic acid (OCA
groups); ‡P  0.05 in comparisons vs. all
groups. CA, cholic acid; D18, day 18 preg-
nant.
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raised serum LDL cholesterol and decreased HDL cholesterol
levels compared with NC females (Fig. 7A) also outside of
pregnancy (Supplemental Fig. S6A). Conversely, OCA feeding
resulted in decreased total serum cholesterol levels compared
with NC controls, which was associated with a reduction in
serum HDL cholesterol concentrations (Fig. 7A). Serum HDL
cholesterol was also reduced in nonpregnant OCA-fed mice
(Supplemental Fig. S6A). CA feeding did not alter serum
triglyceride levels in pregnant females, but OCA diet reduced
serum triglyceride levels, and a further decrease was observed
in CA OCA-fed females (Fig. 7A). In contrast, no significant
changes were observed in serum triglyceride levels in nonpreg-
nant females (Supplemental Fig. S6A).
In the liver, CA, OCA, and CA  OCA supplementation of
pregnant females led to hepatic cholesterol accumulation com-
pared with the NC control group (Fig. 7B). In nonpregnant
females, hepatic cholesterol levels were significantly lower
with OCA supplementation alone compared with CA and
CA  OCA-fed mice (Supplemental Fig. S6B).
Taken together, these data led us to conclude that OCA
administration does not ameliorate maternal dyslipidemia dur-
ing hypercholanemic gestation.
OCA administration during hypercholanemic pregnancy does
not reverse fetal dyslipidemia. Because maternal dyslipidemia is
commonly associated with fetal dyslipidemia, we next inves-
tigated the fetal lipid profile. Maternal CA feeding significantly
increased fetal serum cholesterol levels, including LDL cho-
lesterol, and this was not altered by maternal CA  OCA
supplementation (Fig. 8A). In parallel, fetal serum HDL cho-
lesterol concentrations were reduced in maternal CA and CA
OCA supplementation groups. Fetal circulating triglycerides
were increased in fetuses from CA-fed mothers and were not
improved by maternal CA  OCA feeding (Fig. 8A). Of note
is that maternal OCA feeding alone had no effect on fetal total
and LDL or HDL cholesterol levels or triglyceride and FFA
concentrations (Fig. 8A).
Fetal hepatic cholesterol and FFA content were increased in
fetuses from CA  OCA-fed mothers compared with NC
mothers (Fig. 8B). However, maternal OCA diet alone did not
affect fetal cholesterol and FFA accumulation in the liver (Fig.
8B). A trend for increased hepatic cholesterol and FFA was
also observed in fetuses from CA-fed mothers compared with
NC controls, although it did not reach statistical significance
(Fig. 8B).
To assess a potential relationship between fetal and placental
lipid levels, the placental lipid content on D18 of gestation was
also evaluated. However, no significant changes in placental
cholesterol, triglycerides, or FFA content were registered be-
tween different groups (Fig. 8C).
We subsequently aimed to establish whether the changes in
the fetal lipid profile on D18 of gestation were due to shifts in
lipid de novo biosynthesis and transport in the fetal liver or
placenta. Maternal bile acid feeding did not impact fetal
hepatic Hmgcr, Fas, or Fatp4 expression (Fig. 9A). However,
maternal CA  OCA feeding led to a significant increase in
placental expression of the cholesterol transporter Abca1 com-
pared with NC placentas (Fig. 9B). Interestingly, maternal CA
and CA OCA supplementation, but not maternal OCA alone,
resulted in a significant increase in Fatp4 placental expression
compared with NC controls (Fig. 9B). Taken together, these
data lead us to conclude that OCA administration does not
ameliorate fetal dyslipidemia during hypercholanemic gesta-
tion.
DISCUSSION
ICP is the commonest gestational liver disease and can lead
to adverse fetal outcomes (19, 21, 40). Increased rates of
stillbirth, spontaneous preterm birth, and meconium-stained
amniotic fluid have been reported in pregnancies with high
maternal serum concentrations of bile acids (19, 21, 40), likely
related to fetal exposure to high bile acid concentrations (7).
Although UDCA treatment of ICP has been shown to reduce
maternal bile acid levels in some studies (23), it is not effective
in all patients (8), and it does not return fetal bile acid levels to
normal concentrations (20). The present study shows that OCA
Table 1. Effect of pregnancy on hepatic mRNA expression of key bile acid homeostasis genes
NC CA OCA CA  OCA
NP P NP P NP P NP P
Shp 2.06 	 0.35 0.74 	 0.14* 3.36 	 0.63 2.59 	 0.49 1.78 	 0.39 1.12 	 0.19 3.46 	 0.49 2.15 	 0.21*
Cyp7a1 1.37 	 0.37 1.59 	 0.27 0.004 	 0.001 0.004 	 0.002 0.66 	 0.21 0.14 	 0.02* 0.006 	 0.0023 0.005 	 0.001
Ntcp 0.77 	 0.21 0.19 	 0.05* 0.29 	 0.06* 0.13 	 0.02* 0.36 	 0.03 0.15 	 0.01* 0.28 	 0.05 0.14 	 0.01*
Bsep 1.74 	 0.38 1.02 	 0.21 2.78 	 0.36 1.98 	 0.25 2.05 	 0.37 1.05 	 0.17* 2.62 	 0.34 1.76 	 0.15*
Mrp3 1.31 	 0.12 0.23 	 0.13* 2.68 	 0.41 0.59 	 0.11* 1.07	 0.17 0.09 	 0.01* 2.28 	 0.29 0.63 	 0.08*
Mrp4 1.17 	 0.12 1.25 	 0.40 4.87 	 0.21 3.11 	 0.48* 1.56 	 0.28 0.63 	 0.11* 4.58 	 0.61 3.412 	 0.34
Data are presented as means	 SE; n 
 3–6 mice. CA, cholic acid; NC, normal chow diet; NP, nonpregnant; OCA, obeticholic acid; P, pregnant. Relative
mRNA expression of target genes in NP and P females fed the same diet. *P  0.05 vs. NP females fed the same diet.
Table 2. Effect of pregnancy on mRNA expression of key bile acid homeostasis genes in the terminal ileum
NC CA OCA CA  OCA
NP P NP P NP P NP P
Shp 3.17 	 1.96 3.93 	 0.36 229.70	 57.30 76.18	 14.53* 670.4 	 211.6 322.50	 80.76 398.90	 73.87 167.70	 36.85*
Fgfr15 1.47 	 0.57 0.27 	 0.14 4.29	 0.27 2.23	 0.40* 2.88 	 0.55 2.08	 0.64 4.10	 0.62 3.20	 0.66
Data are presented as means	 SE; n 
 3–6 mice. CA, cholic acid; NC, normal chow diet; NP, nonpregnant; OCA, obeticholic acid; P, pregnant. Relative
mRNA expression of target genes in NP and P females fed the same diet. *P  0.05 vs. NP females fed the same diet.
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administration in a mouse model of hypercholanemia, as seen
in ICP, is not detrimental to the mother or fetus and improves
fetal hypercholanemia.
In our model, CA feeding led to significantly raised total bile
acids in fetal serum. This was largely due to an increase in
taurine-conjugated CA and DCA. Although the fetus synthe-
sizes bile acids from early pregnancy onward, maternal bile
acids can also cross the placenta and contribute to the fetal bile
acid pool (29). Unconjugated and, at much lower levels,
taurine-conjugated CA and DCA were also raised in the serum
of CA-fed mothers. In the fetal compartment, DCA must be
maternally derived since the fetus cannot synthesize secondary
bile acids due to the absence of gut flora, and it is possible that
CA is also being transferred from the mother. However, it is
Fig. 6. Expression of key bile acid homeo-
stasis genes in the fetoplacental unit. A:
mRNA expression of genes regulating bile
acid synthesis and transport in the fetal liver.
B: mRNA expression of genes regulating
bile acid transport in the placenta. Data are
presented as means	 SE; n 
 5–6 mice.
*P  0.05 in comparisons vs. normal chow
diet (NC) and obeticholic acid (OCA)
groups; #P  0.05 in comparisons vs. NC;
‡P  0.05 in comparisons vs. all groups;
†P 0.05 in comparisons vs. NC and cholic
acid (CA) groups. D18, day 18 pregnant.
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not known whether there is preferential transport of more
hydrophilic taurine conjugates across the placenta or increased
taurine conjugation occurring in the fetal liver. We have
previously observed in humans that the ratio of conjugated to
unconjugated bile acids is higher in umbilical cord blood than
in maternal serum (20).
OCA treatment during hypercholanemic gestation signifi-
cantly reduced fetal total serum bile acid levels due to a
reduction in DCA, TDCA, and TCA compared with fetuses of
untreated hypercholanemic mothers. Furthermore, analysis of
fetal serum showed that OCA crosses the placenta and is
present in the fetal compartment, predominantly as T-OCA. In
line with this, hepatic Cyp7a1 expression was reduced in
fetuses from OCA-fed mice and further reduced in both CA
and CA  OCA-fed groups. Interestingly, OCA treatment of
hypercholanemic mothers was associated with an upregulation
of placental transporters Mrp2 (at the maternal-facing apical
membrane) and Oatp1b2 (basolateral membrane), which sug-
gests enhanced elimination of fetal bile acids via the placenta.
Increased placental expression of MRP2 has previously been
Fig. 7. Effects of hypercholanemia and obe-
ticholic acid (OCA) treatment during preg-
nancy on serum and hepatic lipid levels. A:
serum lipid levels. B: hepatic lipid levels.
Data are presented as means	 SE; n
 4–6
mice. ‡P  0.05 in comparisons vs. all
groups; *P  0.05 in comparisons vs. nor-
mal chow diet (NC) and OCA groups. CA,
cholic acid; D18, day 18 pregnant; FFAs,
free fatty acids; TGs, triglycerides.
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Fig. 8. Effects of hypercholanemia and obeticholic acid
(OCA) treatment on lipid levels in the fetoplacental unit. A:
fetal serum lipid levels. B: fetal hepatic lipid levels. C:
placental lipid levels. Data are presented as means	 SE;
n 
 4–6 mice. *P  0.05 in comparisons vs. normal chow
diet (NC) and OCA groups; #P  0.05 in comparisons vs.
NC; $P  0.05 in comparisons vs. OCA group. CA, cholic
acid; FFAs, free fatty acids; TGs, triglycerides.
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associated with reduced bile acids in the fetal compartment in
ICP pregnancies following UDCA treatment (3). Protein ex-
pression and bile acid transport studies would be required to
confirm whether enhanced placental bile acid detoxification is
responsible for this reduction in serum bile acids. The impact
of OCA on fetal bile acid levels is of clinical interest due to the
recent approval of OCA as a treatment for patients with PBC,
as women with PBC may already be receiving OCA treatment
when they become pregnant. In our study, we did not observe
any detrimental effect of OCA on the fetus, in agreement with
a previous study that found no impact on resorptions, number
of fetuses, or fetal growth (10). However, detailed pathological
investigations are required to assess the safety of fetal exposure
to OCA.
In contrast to the fetus, maternal total serum bile acid levels
were not reduced by OCA treatment. Furthermore, OCA treat-
ment did not induce significant shifts in hepatic mRNA ex-
pression of bile acid homeostasis genes. These findings differ
from a previous study of an estrogen-induced cholestasis ro-
dent model reporting that OCA treatment induced bile flow and
hepatocyte expression of Shp, Bsep, and Mrp-2 while repress-
ing Ntcp and Cyp7a1 expression (15). A more recent study of
estrogen-induced cholestasis in mice showed that OCA treat-
ment did not upregulate mRNA expression of FXR targets in
the liver or placenta but did increase hepatic FXR protein
levels. Total serum bile acid levels were reduced in mothers;
however, serum bile acids were only mildly elevated in this
model (10). In contrast, a study investigating the effect of OCA
administration to Mdr2/ mice found that dietary 0.03%
OCA supplementation failed to exert any effect on bile flow
and composition. This study further reported that both OCA
and INT-767, a dual FXR and TGR5 agonist, were effective in
reducing Cyp7a1 and Cyp8b1 gene expression, but only INT-
767 administration resulted in increased hepatic Shp gene
expression and BSEP protein expression (4). A possible expla-
nation is that despite a far higher affinity of FXR for OCA, due
to the activation of FXR by CA-feeding, this limited the impact
of OCA in our study. This is perhaps surprising given that CA
is a weak agonist of FXR [EC50 
 586 M (25) in comparison
with OCA (EC50 
 99nM (42)]. In line with this, CA has
previously been shown to only partially induce BSEP in vitro
in comparison with the natural FXR ligand CDCA (25). A
possible explanation is the 10 times higher abundance of CA as
compared with OCA, at least as measured in serum, which
Fig. 9. Effects of hypercholanemia and obe-
ticholic acid (OCA) treatment on lipid ho-
meostasis genes in the fetoplacental unit. A:
expression of key hepatic lipid biosynthesis
and transport genes in the fetal liver. B:
placental expression of lipid transport genes.
Data are presented as means	 SE; n
 4–6
mice. #P  0.05 in comparisons vs. normal
chow diet (NC). CA, cholic acid.
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limited the impact of OCA. Regardless, OCA administration
alone did not cause the expected robust upregulation of hepatic
FXR targets. Of note is that OCA alone downregulated hepatic
Cyp7a1 expression, and this change was associated with an
upregulation of Shp and Fgf15 in the terminal ileum rather than
hepatic Shp induction. Indeed, previous studies have demon-
strated that OCA administration in rats leads to upregulation of
Shp in the terminal ileum (46) and that, in mice lacking
intestinal Fxr, OCA supplementation does not result in repres-
sion of hepatic Cyp7a1 expression (50). Taken together with
these studies, our findings suggest OCA acts primarily through
ileal FXR to stimulate FGF15 secretion into the portal circu-
lation and repress hepatic Cyp7a1 expression in the maternal
liver rather than via hepatic FXR to modulate the expression of
other hepatic genes involved in bile acid homeostasis. Our
study did not assess the effect of OCA on markers of liver
damage. However, we are aware that CA feeding in twice the
dose in male Swiss Albino mice has previously been shown to
increase serum aspartate transaminase (AST), alanine transam-
inase (ALT), and alkaline phosphatase (AP) levels as well as
hepatocyte size, mitosis, and necrosis (14).
Of note is that the expression of FXR target genes was
decreased overall by pregnancy in both the liver and terminal
ileum, which likely reflects the previously documented de-
creased gestational FXR activity (31, 33, 39). Nonetheless, in
the liver of pregnant NC-fed females, OCA administration did
not appear to efficiently overcome the reduction of FXR
activity, and gene expression levels of FXR targets were
similar. Conversely, in the maternal terminal ileum, the up-
regulation of Shp and Fgf15 expression suggests an increase in
FXR activity induced by OCA administration to NC-fed mice,
but levels remained below those observed outside of pregnancy
and so similarly indicate that OCA is unable to fully activate
FXR in the terminal ileum. In support of this data, we also
observed in a mouse model of gestational diabetes mellitus a
diminished effect of OCA in pregnant mice compared with
nonpregnant controls (30). This highlights the issue that lim-
ited efficacy of FXR agonists should be taken into account in
treatment of pregnant women.
OCA was predominately unconjugated in the serum and the
cecum, in contrast to mice fed OCA alone, where T-OCA
predominated. This indicated a different pattern or activity of
bile acid deconjugating microbiota. Indeed, 16S rRNA gene
sequencing showed that there was an increase in relative
abundance of Bacteroidetes and Proteobacteria (and also Bac-
teroides and Bilophila when analyzed at genus level) in the
cecum of CA  OCA-fed females. We recently reported in
pregnant mice that bile salt hydrolase, which was involved in
deconjugation of bile acids, was exclusively detected in Bac-
teroidetes, with Proteobacteria also enriched in pregnancy,
likely secondary to increased taurine made available after bile
acid deconjugation (39). Bilophila Wadsworthia is known to be
taurine metabolizing (24). These findings suggest that the
predominance of unconjugated OCA in the serum of CA 
OCA-fed mice could be due to an increase of Bacteroidetes
and Proteobacteria in the gut.
OCA administration during hypercholanemic gestation did
not reverse maternal dyslipidemia. Of note is that maternal
OCA supplementation alone resulted in a decrease in serum
total cholesterol due to a reduction in HDL cholesterol. A
similar decrease in serum HDL cholesterol was seen in non-
pregnant females. This decrease is not unexpected, as OCA has
previously been shown to reduce HDL cholesterol in healthy
humans, PBC, and NASH patients (22, 37, 43), and we re-
cently reported that OCA reduced serum cholesterol in a mouse
model of gestational diabetes mellitus (30). Furthermore, he-
patic cholesterol content was raised in all bile acid-supple-
mented mice, albeit to a lesser extent in nonpregnant females
fed an OCA diet. Dyslipidemia with hepatic cholesterol accu-
mulation has previously been suggested to be associated with
Cyp7a1 repression found in cholestasis, as downregulation of
bile acid synthesis from cholesterol leads to cholesterol accu-
mulation in the liver (36, 48), suggesting that cholesterol
accumulation in the liver may be proportional to hepatic
Cyp7a1 repression in our model.
Notably, serum triglycerides were reduced in pregnant mice
that received OCA. This change is in line with previous studies
showing that FXR activation reduces circulating triglycerides
in db/db mice (52). Additionally, in patients with nonalcoholic
fatty liver disease and type 2 diabetes, administration of 50 mg
of OCA daily for 6 wk resulted in decreased serum triglyceride
concentrations (34). However, OCA administration did not
improve fetal dyslipidemia. In fact, maternal CA  OCA
coadministration resulted in accumulation of cholesterol and
FFAs in the fetal liver compared with fetuses of control
mothers. Further investigations are needed to establish whether
the upregulation of expression of placental lipid transporters
Abca1 and Fatp4 may play a role.
In conclusion, OCA administration during hypercholanemic
pregnancy, mimicking the raised serum bile acids observed in
ICP, ameliorated fetal hypercholanemia, although maternal
bile acid levels were not significantly decreased, and maternal
and fetal dyslipidemia was not resolved. Significantly, no
negative effects of maternal OCA treatment on maternal and
fetal morphology, and most importantly, fetal survival, were
observed. Because OCA may be used to treat women of
reproductive age with PBC and NASH, further investigations
into the safety of maternal and fetal exposure to OCA during
pregnancy are warranted.
ACKNOWLEDGMENTS
We thank Piet Beekhof for the help and support with the lipid measure-
ments and Marcus Ståhlman, who performed the UPLC-MSMS for this study.
GRANTS
The research was supported by the Wellcome Trust [092993/Z/10/Z], the
Lauren Page Trust, and the Guy’s and St. Thomas’ Charity. Both J.R.M. and
J.A.K.M., at Imperial College London, received financial support from the
National Institute of Health Research (NIHR) Imperial Biomedical Research
Centre (BRC) based at Imperial College Healthcare National Health Service
(NHS) Trust and Imperial College London. C.W. is an NIHR Senior Investi-
gator and receives support from the NIHR BRC based at Guy’s and St.
Thomas’ NHS Foundation Trust and King’s College London.
The views expressed are those of the authors and not necessarily those of
the NHS, the NIHR, or the Department of Health. According to Wellcome
Trust’s Policy on data, software and materials management and sharing, all
data supporting this study are available on request.
DISCLOSURES
Intercept Pharmaceuticals provided the obeticholic acid used in the exper-
iments described herein. L. Adorini and D. Shapiro are employees of Intercept
Pharmaceuticals. H.-U. Marschall receives grants, personal fees, and nonfi-
nancial support from Intercept Pharmaceuticals.
G209OBETICHOLIC ACID IMPROVES FETAL HYPERCHOLANEMIA
AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00126.2020 • www.ajpgi.org
Downloaded from journals.physiology.org/journal/ajpgi (087.115.078.096) on August 17, 2020.
AUTHOR CONTRIBUTIONS
V.P., G.P., and C.W. conceived and designed research; V.P., J.A.K.M.,
A.W., E.J., and H.-U.M. performed experiments; V.P., S.M., and J.A.K.M.
analyzed data; V.P. and S.M. interpreted results of experiments; V.P., S.M.,
and J.A.K.M. prepared figures; V.P., S.M., and C.W. drafted manuscript; V.P.,
S.M., G.P., C.O., J.A.K.M., A.W., E.J., L.A., D.S., J.R.M., H.-U.M., and C.W.
edited and revised manuscript; S.M. and C.W. approved final version of
manuscript.
REFERENCES
1. Abu-Hayyeh S, Ovadia C, Lieu T, Jensen DD, Chambers J, Dixon PH,
Lövgren-Sandblom A, Bolier R, Tolenaars D, Kremer AE, Syngelaki
A, Noori M, Williams D, Marin JJ, Monte MJ, Nicolaides KH, Beuers
U, Oude-Elferink R, Seed PT, Chappell L, Marschall HU, Bunnett
NW, Williamson C. Prognostic and mechanistic potential of progesterone
sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum.
Hepatology 63: 1287–1298, 2016. doi:10.1002/hep.28265.
2. Ali AH, Carey EJ, Lindor KD. Recent advances in the development of
farnesoid X receptor agonists. Ann Transl Med 3: 5, 2015.
3. Azzaroli F, Mennone A, Feletti V, Simoni P, Baglivo E, Montagnani
M, Rizzo N, Pelusi G, DE Aloysio D, Lodato F, Festi D, Colecchia A,
Roda E, Boyer JL, Mazzella G. Clinical trial: modulation of human
placental multidrug resistance proteins in cholestasis of pregnancy by
ursodeoxycholic acid. Aliment Pharmacol Ther 26: 1139–1146, 2007.
doi:10.1111/j.1365-2036.2007.03462.x.
4. Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda
A, Vecchiotti S, Gonzalez FJ, Schoonjans K, Strazzabosco M, Fickert
P, Trauner M. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces
liver injury in the Mdr2/ (Abcb4/) mouse cholangiopathy model by
promoting biliary HCO3 output. Hepatology 54: 1303–1312, 2011. doi:
10.1002/hep.24537.
6. Baines SD, O’Connor R, Saxton K, Freeman J, Wilcox MH. Compar-
ison of oritavancin versus vancomycin as treatments for clindamycin-
induced Clostridium difficile PCR ribotype 027 infection in a human gut
model. J Antimicrob Chemother 62: 1078–1085, 2008. doi:10.1093/jac/
dkn358.
7. Brouwers L, Koster MP, Page-Christiaens GC, Kemperman H, Boon
J, Evers IM, Bogte A, Oudijk MA. Intrahepatic cholestasis of pregnancy:
maternal and fetal outcomes associated with elevated bile acid levels. Am
J Obstet Gynecol 212: 100.e1–100.e7, 2015. doi:10.1016/j.ajog.2014.07.
026.
8. Chappell LC, Bell JL, Smith A, Linsell L, Juszczak E, Dixon PH,
Chambers J, Hunter R, Dorling J, Williamson C, Thornton JG, Ahmed
I, Arya R, Beckett V, Bhide A, Brown H, Bugg G, Cameron H, Deole N,
Dey M, Dwyer J, Fahel L, Gada R, Girling J, Haestier A, Hughes S,
Indusekhar R, Jones B, Khan R, Kirkpatrick A, Knox E, Lincoln K,
MacDougall M, Majoko F, McIntyre K, Noori M, Oakley W, Preston J,
Ranka P, Rashid M, Salloum M, Samyraju M, Schram C, Sen S, Stone
S, Tan B; PITCHES study group. Ursodeoxycholic acid versus placebo in
women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised
controlled trial. Lancet 394: 849–860, 2019. doi:10.1016/S0140-6736
(19)31270-X.
9. Chappell LC, Gurung V, Seed PT, Chambers J, Williamson C,
Thornton JG; PITCH Study Consortium. Ursodeoxycholic acid versus
placebo, and early term delivery versus expectant management, in women
with intrahepatic cholestasis of pregnancy: semifactorial randomised clin-
ical trial. BMJ 344: e3799, 2012. doi:10.1136/bmj.e3799.
10. Chen W, Gao XX, Ma L, Liu ZB, Li L, Wang H, Gao L, Xu DX, Chen
YH. Obeticholic acid protects against gestational cholestasis-induced fetal
intrauterine growth restriction in mice. Oxid Med Cell Longev 2019: 1–17,
2019. doi:10.1155/2019/7419249.
11. Conti-Ramsden F, McEwan M, Hill R, Wade J, Abraham G, Buck-
eldee O, Williamson C, Knight CL, Girling J, Chappell LC. Detection
of additional abnormalities or co-morbidities in women with suspected
intrahepatic cholestasis of pregnancy. Obstet Med 1753495X1986887,
2019. doi:10.1177/1753495X19868873.
12. Dann AT, Kenyon AP, Wierzbicki AS, Seed PT, Shennan AH, Tribe
RM. Plasma lipid profiles of women with intrahepatic cholestasis of
pregnancy. Obstet Gynecol 107: 106–114, 2006. doi:10.1097/01.AOG.
0000189096.94874.9c.
13. Dixon PH, Williamson C. The pathophysiology of intrahepatic cholesta-
sis of pregnancy. Clin Res Hepatol Gastroenterol 40: 141–153, 2016.
doi:10.1016/j.clinre.2015.12.008.
14. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R,
Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M.
Effects of ursodeoxycholic and cholic acid feeding on hepatocellular
transporter expression in mouse liver. Gastroenterology 121: 170–183,
2001. doi:10.1053/gast.2001.25542.
15. Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour
BM, Sabatino G, Russo G, Castellani D, Willson TM, Pruzanski M,
Pellicciari R, Morelli A. Protective effects of 6-ethyl chenodeoxycholic
acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J
Pharmacol Exp Ther 313: 604–612, 2005. doi:10.1124/jpet.104.079665.
16. Freeman J, Baines SD, Jabes D, Wilcox MH. Comparison of the
efficacy of ramoplanin and vancomycin in both in vitro and in vivo models
of clindamycin-induced Clostridium difficile infection. J Antimicrob Che-
mother 56: 717–725, 2005. doi:10.1093/jac/dki321.
17. Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J
Gastroenterol 15: 2049–2066, 2009. doi:10.3748/wjg.15.2049.
18. Geenes V, Chambers J, Khurana R, Shemer EW, Sia W, Mandair D,
Elias E, Marschall HU, Hague W, Williamson C. Rifampicin in the
treatment of severe intrahepatic cholestasis of pregnancy. Eur J Obstet
Gynecol Reprod Biol 189: 59–63, 2015. doi:10.1016/j.ejogrb.2015.03.
020.
19. Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C.
Association of severe intrahepatic cholestasis of pregnancy with adverse
pregnancy outcomes: a prospective population-based case-control study.
Hepatology 59: 1482–1491, 2014. doi:10.1002/hep.26617.
20. Geenes V, Lövgren-Sandblom A, Benthin L, Lawrance D, Chambers
J, Gurung V, Thornton J, Chappell L, Khan E, Dixon P, Marschall
HU, Williamson C. The reversed feto-maternal bile acid gradient in
intrahepatic cholestasis of pregnancy is corrected by ursodeoxycholic acid.
PLoS One 9: e83828, 2014. doi:10.1371/journal.pone.0083828.
21. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of
pregnancy: Relationships between bile acid levels and fetal complication
rates. Hepatology 40: 467–474, 2004. doi:10.1002/hep.20336.
22. Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M,
Kowdley KV, Vincent C, Bodhenheimer HC Jr, Parés A, Trauner M,
Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E,
Böhm O, Shapiro D. Efficacy of obeticholic acid in patients with primary
biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gas-
troenterology 148: P751–P761.E8, 2015. doi:10.1053/j.gastro.2014.12.
005.
23. Kong X, Kong Y, Zhang F, Wang T, Yan J. Evaluating the effectiveness
and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis
of pregnancy: a meta-analysis (a prisma-compliant study). Medicine (Bal-
timore) 95: e4949, 2016. doi:10.1097/MD.0000000000004949.
24. Laue H, Denger K, Cook AM. Taurine reduction in anaerobic respiration
of Bilophila wadsworthia RZATAU. Appl Environ Microbiol 63: 2016–
2021, 1997. doi:10.1128/AEM.63.5.2016-2021.1997.
25. Lew JL, Zhao A, Yu J, Huang L, De Pedro N, Peláez F, Wright SD,
Cui J. The farnesoid X receptor controls gene expression in a ligand- and
promoter-selective fashion. J Biol Chem 279: 8856–8861, 2004. doi:10.
1074/jbc.M306422200.
26. Martineau M, Raker C, Powrie R, Williamson C. Intrahepatic choles-
tasis of pregnancy is associated with an increased risk of gestational
diabetes. Eur J Obstet Gynecol Reprod Biol 176: 80–85, 2014. doi:10.
1016/j.ejogrb.2013.12.037.
27. Martineau MG, Raker C, Dixon PH, Chambers J, Machirori M, King
NM, Hooks ML, Manoharan R, Chen K, Powrie R, Williamson C. The
metabolic profile of intrahepatic cholestasis of pregnancy is associated
with impaired glucose tolerance, dyslipidemia, and increased fetal growth.
Diabetes Care 38: 243–248, 2015. doi:10.2337/dc14-2143.
28. McDonald JAK, Mullish BH, Pechlivanis A, Liu Z, Brignardello J,
Kao D, Holmes E, Li JV, Clarke TB, Thursz MR, Marchesi JR.
Inhibiting growth of clostridioides difficile by restoring valerate, produced
by the intestinal microbiota. Gastroenterology 155: 1495–1507.e15, 2018.
doi:10.1053/j.gastro.2018.07.014.
29. McIlvride S, Dixon PH, Williamson C. Bile acids and gestation. Mol
Aspects Med 56: 90–100, 2017. doi:10.1016/j.mam.2017.05.003.
30. McIlvride S, Nikolova V, Fan HM, McDonald JAK, Wahlström A,
Bellafante E, Jansen E, Adorini L, Shapiro D, Jones P, Marchesi JR,
Marschall HU, Williamson C. Obeticholic acid ameliorates dyslipidemia
but not glucose tolerance in mouse model of gestational diabetes. Am J
Physiol Endocrinol Metab 317: E399–E410, 2019. doi:10.1152/ajpendo.
00407.2018.
G210 OBETICHOLIC ACID IMPROVES FETAL HYPERCHOLANEMIA
AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00126.2020 • www.ajpgi.org
Downloaded from journals.physiology.org/journal/ajpgi (087.115.078.096) on August 17, 2020.
31. Milona A, Owen BM, Cobbold JF, Willemsen EC, Cox IJ, Boudjelal
M, Cairns W, Schoonjans K, Taylor-Robinson SD, Klomp LW,
Parker MG, White R, van Mil SW, Williamson C. Raised hepatic bile
acid concentrations during pregnancy in mice are associated with reduced
farnesoid X receptor function. Hepatology 52: 1341–1349, 2010. doi:10.
1002/hep.23849.
32. Milona A, Owen BM, van Mil S, Dormann D, Mataki C, Boudjelal M,
Cairns W, Schoonjans K, Milligan S, Parker M, White R, Williamson
C. The normal mechanisms of pregnancy-induced liver growth are not
maintained in mice lacking the bile acid sensor Fxr. Am J Physiol
Gastrointest Liver Physiol 298: G151–G158, 2010. doi:10.1152/ajpgi.
00336.2009.
33. Moscovitz JE, Kong B, Buckley K, Buckley B, Guo GL, Aleksunes
LM. Restoration of enterohepatic bile acid pathways in pregnant mice
following short term activation of Fxr by GW4064. Toxicol Appl Phar-
macol 310: 60–67, 2016. doi:10.1016/j.taap.2016.08.021.
34. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes
M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski
M, Shapiro D. Efficacy and safety of the farnesoid X receptor agonist
obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty
liver disease. Gastroenterology 145: 574–82.e1, 2013. doi:10.1053/j.
gastro.2013.05.042.
35. Mullish BH, Pechlivanis A, Barker GF, Thursz MR, Marchesi JR,
McDonald JAK. Functional microbiomics: Evaluation of gut microbiota-
bile acid metabolism interactions in health and disease. Methods 149:
49–58, 2018. doi:10.1016/j.ymeth.2018.04.028.
36. Murphy C, Parini P, Wang J, Björkhem I, Eggertsen G, Gåfvels M.
Cholic acid as key regulator of cholesterol synthesis, intestinal absorption
and hepatic storage in mice. Biochim Biophys Acta 1735: 167–175, 2005.
doi:10.1016/j.bbalip.2005.06.001.
37. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van
Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM,
Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM,
Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research
Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-
cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, ran-
domised, placebo-controlled trial. Lancet 385: 956–965, 2015. doi:10.
1016/S0140-6736(14)61933-4.
38. Nikolova V, Papacleovoulou G, Bellafante E, Borges Manna L, Jansen
E, Baron S, Abu-Hayyeh S, Parker M, Williamson C. Changes in LXR
signaling influence early-pregnancy lipogenesis and protect against dys-
regulated fetoplacental lipid homeostasis. Am J Physiol Endocrinol Metab
313: E463–E472, 2017. doi:10.1152/ajpendo.00449.2016.
39. Ovadia C, Perdones-Montero A, Spagou K, Smith A, Sarafian MH,
Gomez-Romero M, Bellafante E, Clarke LCD, Sadiq F, Nikolova V,
Mitchell A, Dixon PH, Santa-Pinter N, Wahlström A, Abu-Hayyeh S,
Walters JRF, Marschall HU, Holmes E, Marchesi JR, Williamson C.
Enhanced microbial bile acid deconjugation and impaired ileal uptake in
pregnancy repress intestinal regulation of bile acid synthesis. Hepatology
70: 276–293, 2019. doi:10.1002/hep.30661.
40. Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Ilio C, Chambers J,
Kohari K, Bacq Y, Bozkurt N, Brun-Furrer R, Bull L, Estiú MC,
Grymowicz M, Gunaydin B, Hague WM, Haslinger C, Hu Y,
Kawakita T, Kebapcilar AG, Kebapcilar L, Kondrackiene˙ J, Koster
MPH, Kowalska-Kan´ka A, Kupcˇinskas L, Lee RH, Locatelli A, Ma-
cias RIR, Marschall HU, Oudijk MA, Raz Y, Rimon E, Shan D, Shao
Y, Tribe R, Tripodi V, Yayla Abide C, Yenidede I, Thornton JG,
Chappell LC, Williamson C. Association of adverse perinatal outcomes
of intrahepatic cholestasis of pregnancy with biochemical markers: results
of aggregate and individual patient data meta-analyses. Lancet 393:
899–909, 2019. doi:10.1016/S0140-6736(18)31877-4.
41. Papacleovoulou G, Abu-Hayyeh S, Nikolopoulou E, Briz O, Owen
BM, Nikolova V, Ovadia C, Huang X, Vaarasmaki M, Baumann M,
Jansen E, Albrecht C, Jarvelin MR, Marin JJ, Knisely AS, William-
son C. Maternal cholestasis during pregnancy programs metabolic disease
in offspring. J Clin Invest 123: 3172–3181, 2013. doi:10.1172/JCI68927.
42. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Ma-
loney PR, Morelli A, Parks DJ, Willson TM. 6alpha-ethyl-chenodeoxy-
cholic acid (6-ECDCA), a potent and selective FXR agonist endowed with
anticholestatic activity. J Med Chem 45: 3569–3572, 2002. doi:10.1021/
jm025529g.
43. Pencek R, Marmon T, Roth JD, Liberman A, Hooshmand-Rad R,
Young MA. Effects of obeticholic acid on lipoprotein metabolism in
healthy volunteers. Diabetes Obes Metab 18: 936–940, 2016. doi:10.
1111/dom.12681.
44. Pusl T, Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet J Rare
Dis 2: 26, 2007. doi:10.1186/1750-1172-2-26.
45. Tremaroli V, Karlsson F, Werling M, Ståhlman M, Kovatcheva-
Datchary P, Olbers T, Fändriks L, le Roux CW, Nielsen J, Bäckhed F.
Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-
term changes on the human gut microbiome contributing to fat mass
regulation. Cell Metab 22: 228–238, 2015. doi:10.1016/j.cmet.2015.07.
009.
46. Úbeda M, Lario M, Muñoz L, Borrero MJ, Rodríguez-Serrano M,
Sánchez-Díaz AM, Del Campo R, Lledó L, Pastor Ó, García-Bermejo
L, Díaz D, Álvarez-Mon M, Albillos A. Obeticholic acid reduces bacte-
rial translocation and inhibits intestinal inflammation in cirrhotic rats. J
Hepatol 64: 1049–1057, 2016. doi:10.1016/j.jhep.2015.12.010.
47. Van den Abbeele P, Grootaert C, Marzorati M, Possemiers S, Vers-
traete W, Gérard P, Rabot S, Bruneau A, El Aidy S, Derrien M,
Zoetendal E, Kleerebezem M, Smidt H, Van de Wiele T. Microbial
community development in a dynamic gut model is reproducible, colon
region specific, and selective for Bacteroidetes and Clostridium cluster IX.
Appl Environ Microbiol 76: 5237–5246, 2010. doi:10.1128/AEM.00759-10.
48. Wang L, Han Y, Kim CS, Lee YK, Moore DD. Resistance of SHP-null
mice to bile acid-induced liver damage. J Biol Chem 278: 44475–44481,
2003. doi:10.1074/jbc.M305258200.
49. Wikström Shemer E, Marschall HU, Ludvigsson JF, Stephansson O.
Intrahepatic cholestasis of pregnancy and associated adverse pregnancy
and fetal outcomes: a 12-year population-based cohort study. BJOG 120:
717–723, 2013. doi:10.1111/1471-0528.12174.
50. Xu Y, Li F, Zalzala M, Xu J, Gonzalez FJ, Adorini L, Lee YK, Yin L,
Zhang Y. Farnesoid X receptor activation increases reverse cholesterol
transport by modulating bile acid composition and cholesterol absorption
in mice. Hepatology 64: 1072–1085, 2016. doi:10.1002/hep.28712.
51. Zhang Y, Jackson JP, St Claire RL III, Freeman K, Brouwer KR,
Edwards JE. Obeticholic acid, a selective farnesoid X receptor agonist,
regulates bile acid homeostasis in sandwich-cultured human hepatocytes.
Pharmacol Res Perspect 5: e00329, 2017. doi:10.1002/prp2.329.
52. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson
TM, Edwards PA. Activation of the nuclear receptor FXR improves
hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci
USA 103: 1006–1011, 2006. doi:10.1073/pnas.0506982103.
G211OBETICHOLIC ACID IMPROVES FETAL HYPERCHOLANEMIA
AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00126.2020 • www.ajpgi.org
Downloaded from journals.physiology.org/journal/ajpgi (087.115.078.096) on August 17, 2020.
